METASTATIC LUNG NON-SMALL CELL CARCINOMA
Clinical trials for METASTATIC LUNG NON-SMALL CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC LUNG NON-SMALL CELL CARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC LUNG NON-SMALL CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New cocktail targets tough lung cancer in early trial
Disease control OngoingThis early-phase study tests a new drug combination for people with advanced ALK-positive non-small cell lung cancer that has spread or come back. The goal is to find the safest dose of the targeted drug ensartinib when given with standard chemotherapy (carboplatin, pemetrexed) a…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 04:26 UTC
-
Cancer vaccine boosts immunotherapy in advanced lung and Head/Neck tumors
Disease control OngoingThis study tests a vaccine called CIMAvax combined with immunotherapy drugs (nivolumab or pembrolizumab) in people with advanced non-small cell lung cancer or head/neck cancer that has spread. The goal is to find the best dose and see if the combination helps control tumor growth…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated May 26, 2026 04:25 UTC
-
New drug combo shows promise for Hard-to-Treat lung cancer
Disease control OngoingThis study is for people with advanced non-small cell lung cancer that has come back or spread. It tests a combination of two drugs: trametinib, which blocks cancer cell growth, and pembrolizumab, which helps the immune system attack cancer. The goal is to see if this combination…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 04:24 UTC
-
New drug combo targets Hard-to-Treat lung cancer
Disease control OngoingThis early-phase trial tests two experimental drugs, sapanisertib and telaglenastat, in people with advanced non-small cell lung cancer that has spread to the brain or other areas. The goal is to find the safest dose and see if the combination can shrink tumors or slow the diseas…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 04:24 UTC
-
New drug combo aims to outsmart resistant lung cancer
Disease control OngoingThis early-stage trial tests whether adding necitumumab to osimertinib is safe and tolerable for people with advanced EGFR-mutant non-small cell lung cancer that has worsened after previous targeted therapy. About 138 participants will receive the combination to find the best dos…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 04:22 UTC
-
New pill shows promise against tough lung and brain cancers
Disease control OngoingThis study tests an experimental daily pill, BDTX-1535, in about 200 adults with advanced non-small cell lung cancer or glioblastoma (a type of brain tumor). The drug targets specific EGFR mutations that make cancers resistant to other treatments. The goal is to find the safest d…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Black Diamond Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 04:17 UTC
-
New hope for lung cancer patients with brain tumors?
Disease control OngoingThis study tested whether adding a second drug (bevacizumab) to the standard targeted therapy (osimertinib) helps control lung cancer that has spread to the brain. It involved 5 adults with a specific gene mutation (EGFR) whose cancer had not been treated with similar drugs befor…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 04:11 UTC
-
New combo aims to outsmart Drug-Resistant lung cancer
Disease control OngoingThis early-phase trial tests a combination of two drugs, sapanisertib and osimertinib, in people with advanced EGFR-mutant non-small cell lung cancer whose cancer has worsened after previous treatment. The main goal is to find the safest dose and understand side effects. About 36…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 03:57 UTC
-
Experimental combo targets Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests the safety and best dose of sonidegib combined with the immunotherapy pembrolizumab in people with advanced solid tumors that have spread. The goal is to see if this drug pair can shrink tumors or slow their growth. About 36 adults with cancers like m…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 26, 2026 03:55 UTC
-
New drug combo targets tough lung cancer in small early trial
Disease control OngoingThis early-phase study is for people with a specific kind of advanced lung cancer (ALK-positive non-small cell lung cancer) that has gotten worse despite prior ALK-targeted therapy. Researchers are testing a combination of two drugs—brigatinib and bevacizumab—to see what dose is …
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 26, 2026 03:55 UTC
-
New combo therapy aims to boost immune attack on Hard-to-Treat cancers
Disease control OngoingThis study tests whether combining two immunotherapy drugs (durvalumab and tremelimumab) with radiation therapy can shrink tumors in people with metastatic colorectal or non-small cell lung cancer. About 110 participants will receive the drugs alone or with low or high-dose radia…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
New combo aims to tame Immunotherapy's side effects in advanced cancers
Disease control OngoingThis study tests whether adding tocilizumab to standard immunotherapy (ipilimumab and nivolumab) can reduce severe side effects in people with advanced melanoma, lung cancer, or bladder cancer. About 35 participants will receive the combination to see if it is safer and still eff…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 20, 2026 11:57 UTC
-
New drug targets Hard-to-Treat brain tumors in early trial
Disease control OngoingThis early-phase study tests a new drug called WSD0922-FU in 56 people with certain brain cancers (glioblastoma, anaplastic astrocytoma) or lung cancer that has spread to the brain or spinal cord. The drug blocks a protein called EGFR, which helps some cancers grow. The main goal…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 20, 2026 11:56 UTC
-
Cord blood cells engineered to fight lung cancer in early trial
Disease control OngoingThis early-phase study tests a new treatment for people with advanced non-small cell lung cancer that no longer responds to standard immunotherapy. The treatment uses immune cells from donated umbilical cord blood that are genetically modified to better recognize and attack cance…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: University of California, Irvine • Aim: Disease control
Last updated May 20, 2026 11:53 UTC
-
New drug combo aims to halt lung cancer growth
Disease control OngoingThis study tests a new combination of two drugs, osimertinib and telaglenastat, in people with advanced non-small cell lung cancer that has a specific EGFR gene mutation. The goal is to find the safest dose and see how well the drugs work together to stop cancer cells from growin…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New drug combo shows promise for tough lung cancers
Disease control OngoingThis study tests whether combining two drugs—atezolizumab (an immunotherapy that helps the immune system attack cancer) and cobimetinib (a targeted therapy that blocks cancer growth signals)—can shrink tumors or slow disease in people with advanced non-small cell lung cancer that…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
Vitamin a derivative joins immunotherapy in fight against advanced lung cancer
Disease control OngoingThis early-stage trial tests a combination of all-trans retinoic acid (ATRA), a drug made from vitamin A, and atezolizumab, an immunotherapy, in 18 adults with advanced non-small cell lung cancer that has returned or spread. The main goal is to find the safest dose and understand…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: Dwight Owen • Aim: Disease control
Last updated May 13, 2026 15:58 UTC
-
New combo therapy shows promise for HIV patients with advanced cancer
Disease control OngoingThis early-phase trial is testing the safety of combining two cancer drugs—nivolumab and cabozantinib—in people with HIV who have advanced solid tumors. The study includes 8 participants with various cancers that have spread. The goal is to see if the combination can shrink or st…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:38 UTC
-
New drug combo shows promise in Hard-to-Treat cancers
Disease control OngoingThis study tests a combination of two drugs, cediranib and olaparib, in people with advanced or inoperable solid tumors, including certain breast, lung, and pancreatic cancers. The goal is to see if the combo can shrink tumors or slow their growth by blocking enzymes that cancer …
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 08, 2026 12:04 UTC
-
New cocktail aims to outsmart Drug-Resistant lung cancer
Disease control OngoingThis study tests whether adding two antibody drugs (necitumumab and trastuzumab) to the standard pill osimertinib can shrink tumors in people with advanced EGFR-mutated lung cancer that has stopped responding to osimertinib alone. About 30 adults with stage IV non-small cell lung…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated May 06, 2026 16:01 UTC
-
New drug combo aims to boost radiation for brain tumors from lung cancer
Symptom relief OngoingThis early-phase trial tests a drug called berzosertib combined with whole brain radiation for people with lung cancer that has spread to the brain. The main goal is to find the safest dose and check for side effects. About 15 adults with non-small cell, small cell, or neuroendoc…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Symptom relief
Last updated May 26, 2026 04:12 UTC